Ampsource Biopharma Shanghai Inc.

Pharmab, Inc.

Furen Pharmaceutical Group Co., Ltd

Kaifeng Pharmaceutical (Group) Co., Ltd.

Zhengzhou Gensciences Inc.

Shuya Wang

Zijia Ren

Wenwen Wang

Qilei Wang

Jie Gao

Jing Li

Qiang Li

Yali Wang

Yu Wang

Yuanli Li

Yongjuan Gao

Naichao Sun

Xian Chen

Shuang Wang

Wenchen Zhu

Chenggong Zhu

Luyan Zhu

Xiaoshan Wang

Bin Liu

Zhi Li

Ming Jiang

Lirui Wang

Songlin Zhu

Hongsheng Su

Lingli Huang

Haitao Hu

Lili Zhang

Chunfeng Xiao

Disclosed are a coagulation factor VIII fusion protein which is conjugated with polyalkylene glycol and which has an extended cyclic half-life, a preparation method therefor and a use thereof, wherein the active moiety of the coagulation factor VIII is directly linked or indirectly linked by a peptide linker to a fusion partner, and the fusion protein is further conjugated to a polyalkylene glycol. The half-life is significantly increased compared to an FVIII fusion protein modified without polyalkylene glycol.

FVIII fusion protein and use thereof

A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin &#x3b2;-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.

Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same

Growing community of inventors

Kaifeng, China

Shuya Wang